top of page
Scemblix (Asciminib)
SCEMBLIX is indicated for the treatment of adult patients with:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
Ph+ CML in CP with the T315I mutation

Scemblix (Asciminib)

  • Take Scemblix exactly as your healthcare provider tells you. Do not change your dose or schedule or stop treatment unless your healthcare provider tells you to. Take Scemblix tablets without food. You should avoid eating for at least 2 hours before and 1 hour after taking Scemblix. Swallow the tablets whole. Do not break, crush, or chew the tablets. If you take Scemblix 1 time a day and miss a dose by more than 12 hours, skip the missed dose and take your next dose at your regular time. If you take Scemblix 2 times a day and miss a dose by more than 6 hours, skip the missed dose and take your next dose at your regular time.
bottom of page